Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Breast Cancer

 

Vaccine Therapy for HER2+ Stage IV Breast Cancer
Phase II Study to Evaluate the Development of HER2/neu (HER2)-Specific Memory T Cells After HER2 Peptide-Based Vaccination in Patients with Advanced Stage HER2+ Breast Cancer

Investigator: Lupe Salazar, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01729884

The BEACON Study-Breast Cancer Outcomes With NKTR-102 (UW11054)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine

Investigator: Jennifer M. Specht, MD;   Conditions: Locally Recurrent Breast Cancer, Metastatic Breast Cancer;    Status: Recruiting;   Study ID: NCT01492101

Pertuzumab in Combination With Herceptin and Vinorelbine for Metastatic or HER2-Positive Breast Cancer (UW12012)
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Temporarily On Hold;   Study ID: NCT01565083

Triple Negative (6628)
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel (Abraxane) and Bevacizumab (Avastin) Followed by Maintenance Targeted Therapy With Bevacizumab (Avastin) and Erlotinib (Tarceva)

Investigator: Jennifer Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT00733408

PARP Inhibitor ABT-888 with Cisplatin and Vinorelbine (7161)
Phase I Study of ABT-888 (Veliparib) in Combination With Cisplatin and Vinorelbine (Navelbine) for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Investigator: Eve Rodler, MD;   Conditions: Advanced Breast Cancer;    Status: Recruiting;   Study ID: NCT01104259

High-dose Methotrexate + Liposomal Cytarabine (6954)
A Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients with Parenchymal and Leptomeningeal Metastases from Breast Cancer

Investigator: Maciej Mrugala, MD, PhD;   Conditions: Stage IV Breast Cancer, Central Nervous System Involvement/Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Tumors Metastatic to Brain;    Status: Open;   Study ID: NCT00992602

Ampligen w/Vaccine Therapy for Stage II-IV HER2-Positive Breast Cancer (7425)
Phase I-II Study of HER2 Vaccination with poly(I) poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients

Investigator: Lupe Salazar, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01355393

Vorinostat + Hormone Therapy for Stage IV Breast Cancer (7841)
A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B

Investigator: Hannah Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01720602

I-SPY2 Trial (7518)
I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)

Investigator: Larissa Korde;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01042379

FES Imaging in Response to Hormone Therapy (6357)
A Phase 2 Study of [18F]fluoroestradiol (FES) Imaging and Response to Hormonal Therapy

Investigator: David Mankoff, M.D., PhD ;   Conditions: Breast Cancer;    Status: Recruiting